SMARCB1 and cancer: A definitive cancer risk cannot be extrapolated for patients with distal 22q11.2 deletion syndrome, but deletions encompassing SMARCB1 should receive vigilant surveillance from birth to adulthood as large deletions may predispose to late occurrence of MRT [22, 36].